If you are the kind of person who sees 'Boston Children's uses AI to unlock new diagnoses' and wonders whether you are already behind, the easy mistake is to stare at the AI headline and miss the workflow change underneath [C001]. The contrarian read is simple: most of the rare-disease breakthrough here looks like recomputing old cases, not AI having a sudden flash of genius [C002].
What the source actually says is narrower than the headline. Boston Children's says its AI-assisted genetics workflow helped produce 40+ diagnoses that had stayed unresolved for a long time. But the most decision-changing number is 744: in the hospital's 2024 report, among families who had previously tested negative, 64% of the new answers could have come from rechecking older DNA test results. Only 8% needed a fuller DNA test.
That shifts the lesson. Boston also says routine genetic testing gives an answer in about 30% of cases, so the real operational work is what happens after the first 'no answer.' The hard part is building a system that keeps working on the unresolved 70% instead of treating the first negative result as the end of the road.
Boundary matters. This is Boston Children's own rare-disease workflow, using its prior DNA cases and its own reanalysis process. It does not show that every hospital, every dataset, or every AI tool will produce the same lift. A news update is worth your attention not because it lists new features, but because it changes your next decision. Share this with anyone who reads AI healthcare headlines as product magic instead of workflow change.